# Alexander C. J. van Akkooi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alexander-c-j-van-akkooi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,243 |
| Field | Cutaneous Melanoma Detection and Management |
| h-index | 55 |
| i10-index | 187 |
| Last Known Institution | The University of Sydney |
| OpenAlex ID | https://openalex.org/A5075441317 |
| ORCID iD | https://orcid.org/0000-0002-3262-6935 |
| Works | 475 |

## Researcher papers

- [Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma/)
- [Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma](https://scholariq.org/papers/tumor-infiltrating-lymphocyte-therapy-or-ipilimumab-in-advanced-melanoma/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?](https://scholariq.org/papers/clinical-relevance-of-melanoma-micrometastases-and-lt-0-1-mm-in-sentinel-nodes/)
- [Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients](https://scholariq.org/papers/sentinel-node-tumor-burden-according-to-the-rotterdam-criteria-is-the-most/)
- [ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee](https://scholariq.org/papers/esmo-consensus-conference-recommendations-on-the-management-of-metastatic/)

## Researcher topics

- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Nonmelanoma Skin Cancer Studies](https://scholariq.org/topics/nonmelanoma-skin-cancer-studies/)

## Researcher university

- [The University of Sydney](https://scholariq.org/institutions/the-university-of-sydney/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.